Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

IGF-1 LR3 and Metformin Interaction: Monitor | Peptide Database

Compound Profiles IGF-1 LR3 Modified Growth Factor Analog | Muscle Growth Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels f

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

IGF-1 LR3

Modified Growth Factor Analog | Muscle Growth

Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.

Metformin

Biguanide | AMPK Activator & Longevity Research

Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation.

Combined Organ Load

Frequently Asked Questions

Can I take IGF-1 LR3 with Metformin?

Yes, but with caution. May mitigate insulin resistance. Regular monitoring is advised.

Is IGF-1 LR3 and Metformin safe together?

Based on documented research, this combination is considered monitor. No critical safety flags identified for this pair.

What are the interactions between IGF-1 LR3 and Metformin?

May mitigate insulin resistance. This assessment has 90% confidence and is based on documented research data.

How should I time IGF-1 LR3 and Metformin?

IGF-1 LR3 has a half-life of 20-30 hours and Metformin has a half-life of ~5 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Corrects age-related glucose tolerance disturbances in primate studies. Reduces incidence and magnitude of metabolic syndrome. Helps control blood sugar through pancreatic function support. Impacts differentiation of pancreatic cells during aging. Improves endocrine function of the pancreas. Addresses age-related imbalance of pancreatic function. Directly interacts with DNA to regulate pancreatic gene expression.

Source: peptide-db.com ↗

Community Research

Join others researching Ecdysterone — share findings, ask questions, and learn from real experiences Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism. Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling. ERbeta is expressed in skeletal muscle tissue, and its activation triggers downstream anabolic signaling cascades including the PI3K/Akt pathway, which promotes muscle protein synthesis and inhibits protein degradation. This pathway converges on mTOR (mechanistic target of rapamycin), a master regulator of muscle hypertrophy, leading to increased translation of muscle-specific proteins. Importantly, ecdysterone does not activate estrogen receptor alpha (ERalpha), which is responsible for the feminizing effects of estrogens, nor does it bind to the androgen receptor, glucocorticoid receptor, or mineralocorticoid receptor. This selectivity explains why ecdysterone does not produce the hormonal side effects associated with anabolic steroids -- there is no testosterone suppression, no testicular atrophy, no gynecomastia, no liver toxicity, and no virilization in women. Additional proposed mechanisms include enhanced nitrogen retention in muscle tissue, improved calcium handling in muscle fibers leading to better contractile efficiency, and mild anti-inflammatory effects that may support recovery from exercise-induced muscle damage. Some in vitro studies also suggest ecdysterone may increase satellite cell proliferation, which could contribute to long-term muscle growth capacity.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Anastrozole is administered orally as a tablet. It is well absorbed with approximately 83-85% bioavailability, and absorption is not significantly affected by food. The long half-life of 40-50 hours supports dosing every other day or every three days for most estrogen management protocols, rather than daily dosing which is primarily reserved for the medical breast cancer indication. On-cycle estrogen management (conservative) 0.25mg Every other day (EOD) or every 3 days (E3D) Oral On-cycle estrogen management (moderate) 0.5mg On-cycle estrogen management (aggressive) 1mg Every other day (EOD) TRT adjunct (low-dose) 0.125-0.25mg Twice weekly or as needed based on bloodwork Breast cancer treatment (medical) Once daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent HDL cholesterol suppression (significant, often 30-50% reduction) LDL cholesterol elevation Suppression of endogenous testosterone production via HPG axis negative feedback Mild gastrointestinal discomfort or nausea Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds) Oily skin and mild acne Decreased appetite in some users

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →